A Novel Injectable Hydrogel Matrix Loaded With 90Y Microspheres for the Treatment of Solid Tumors

Anticancer Res. 2022 Feb;42(2):827-836. doi: 10.21873/anticanres.15540. Epub 2022 Jan 29.

Abstract

Background/aim: The need to concentrate the anti-tumoral activity of 90Y only to the targeted tumor, while minimizing its off-target effects, led to the development of an innovative device (BAT-90) composed of a hydrogel matrix and 90Y microspheres.

Materials and methods: This in vivo randomized study was planned to assess the efficacy, safety, and biodistribution of BAT-90 in 46 rabbits implanted with a VX2 tumor. The effects of BAT-90 were compared to those of 90Y microspheres and the hydrogel matrix.

Results: BAT-90 localized effectively the 90Y radiation in the injection site, minimizing dispersion of the microspheres in the target and distant organs of the treated animals.

Conclusion: BAT-90 can be administered as an adjuvant treatment to clear surgical margins from any potential minimal residual disease, or as an alternative to other loco-regional treatments for non-resectable tumors.

Keywords: 90Y-microspheres; Rabbit models; loco-regional therapy.

MeSH terms

  • Animals
  • Antineoplastic Agents / administration & dosage*
  • Antineoplastic Agents / chemistry
  • Antineoplastic Agents / pharmacokinetics
  • Chemoradiotherapy, Adjuvant
  • Hydrogels / administration & dosage*
  • Hydrogels / chemistry
  • Hydrogels / pharmacokinetics
  • Injections
  • Kidney Neoplasms / therapy
  • Male
  • Microspheres*
  • Neoplasm, Residual
  • Neoplasms, Experimental
  • Rabbits
  • Tissue Distribution
  • Treatment Outcome
  • Yttrium Radioisotopes / administration & dosage*
  • Yttrium Radioisotopes / chemistry
  • Yttrium Radioisotopes / pharmacokinetics

Substances

  • Antineoplastic Agents
  • Hydrogels
  • Yttrium Radioisotopes
  • Yttrium-90